Bayer simultaneously submitted a marketing application for non-naloxone heart failure indications in China and the United States

Zhitong
2025.01.11 08:40

On January 11th, Bayer announced that it has submitted a marketing application for finerenone for heart failure indications to both the Center for Drug Evaluation of the National Medical Products Administration of China and the U.S. Food and Drug Administration, intended for adult heart failure patients with left ventricular ejection fraction (LVEF) ≥ 40%, specifically for those with mildly reduced or preserved LVEF heart failure

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.